🚨 Wall Street is Watching – Hoth Therapeutics, Inc. (NASDAQ: HOTH) Could Be the Next 100% Runner
Published: Thu, 03/13/25
Updated: Thu, 03/13/25
Get the Full Story - Breaking News Released! Download our Mobile App📱
SPONSORED
.
🚨 Wall Street is Watching – Hoth Therapeutics, Inc. (NASDAQ: HOTH) Could Be the Next 100% Runner
Hoth Therapeutics, Inc.
(NASDAQ: $HOTH)
===========================
Alert Price - $1.08 per share
Market Cap - $14.2M
Avg. Volume - $9,471,037
Members,
We're thrilled to unveil our latest pick, Hoth Therapeutics, Inc. (NASDAQ: HOTH)—a biotech innovator developing next-generation therapies for cancer, Alzheimer’s, inflammatory bowel disease, atopic dermatitis, and more. With a strong pipeline and a patient-centric approach, HOTH is making major strides in immunology and oncology.
We believe NASDAQ: HOTH could be a boomer trade, with a 100% surge in sight and a potential 339% upside based on analyst projections. With breakthrough drug development and a growing footprint in high-demand healthcare markets, this stock presents a compelling short-term setup while holding long-term upside in the biotech space.
Technical Overview
Hoth Therapeutics, Inc. (NASDAQ: HOTH) shares
are down slightly by 1.83% in Thursday’s trading session, but the technical outlook suggests a major breakout could be on the horizon. A fully formed falling wedge pattern has developed on the chart, and liquidity has been swept to the downside. The stock attempted to break out of this wedge in early March 2025, but the move was faded due to broader market consolidation, influenced by recent uncertainties surrounding Trump’s tax policy. However, the current setup indicates that a breakout
remains imminent, with a potential 100% surge in sight.
The 12-hour chart shows that the Relative Strength Index (RSI) currently sits at 50.66, positioning the stock in a neutral zone. This is a strong indicator that NASDAQ: HOTH could gain traction as buyers begin to accumulate, capitalizing on its stability. The stock’s ability to maintain strength at this level suggests that momentum
could shift rapidly if bullish pressure increases.
Key Fibonacci retracement levels are also aligning with this bullish setup. The 65% and 61.8% Fibonacci zones are acting as the primary
breakout points, which correspond to the $1.40–$1.50 price range. If NASDAQ: HOTH successfully breaks through these levels, a strong upward move could follow, validating the 100% surge potential. This setup is further reinforced by increasing trading volume and early signs of buyer interest, which could trigger the anticipated breakout.
With volume ticking up and key resistance levels within reach, Hoth Therapeutics, Inc. (NASDAQ: HOTH)
shares are shaping up for a move that could catch many off guard. Historically, setups like this don’t stay quiet for long—once momentum kicks in, those on the sidelines may find themselves chasing the action.
About Hoth Therapeutics, Inc. (NASDAQ: HOTH)
Founded in 2017, Hoth Therapeutics, Inc. (NASDAQ: HOTH). is a
clinical-stage biopharmaceutical company dedicated to developing innovative therapies for unmet medical needs. Headquartered in New York, the company focuses on advancing treatments across multiple therapeutic areas, including dermatology, oncology, neurology, and immunology.
Hoth Therapeutics is actively developing HT-001, a
topical formulation in Phase II clinical trials aimed at treating rash and skin disorders linked to tyrosine kinase epidermal growth factor receptor inhibitors. Additionally, the company is working on HT-KIT for mast-cell-derived cancers and anaphylaxis, HT-TBI for traumatic brain injury and ischemic stroke, and HT-ALZ, a potential treatment for Alzheimer’s disease and other neuroinflammatory conditions. Other pipeline candidates include HT-004 for asthma and allergies, HT-003 for acne,
psoriasis, and inflammatory bowel diseases, as well as HT-005 for lupus.
Beyond its core pipeline, Hoth Therapeutics is developing the BioLexa Platform, a proprietary drug compound currently in Phase I trials for eczema treatment. The company has secured multiple licensing agreements with esteemed institutions such as George Washington University,
Virginia Commonwealth University, North Carolina State University, and the University of Cincinnati. Additionally, it collaborates with Weill Cornell Medicine to further the development of HT-003.
Since its IPO in 2019, Hoth Therapeutics has remained committed to pioneering novel treatments that address significant medical
challenges, leveraging strategic partnerships and cutting-edge research to push the boundaries of biotechnology.
“Submitting an Expanded Access application is an important step in our commitment to ensuring
patients who may benefit from HT-001 have the opportunity to receive this promising treatment, we remain dedicated to advancing solutions that address critical unmet medical needs and improve quality of life for patients undergoing cancer treatment."
"These findings
demonstrate the potential of HT-001 as a safe and effective therapy for EGFR inhibitor-associated skin toxicities, with a significant unmet need for long-term, well-tolerated treatment options, HT-001 could offer relief to cancer patients experiencing debilitating skin reactions."
"These compelling findings reinforce GDNF's potential to fundamentally alter the way we approach obesity treatment, Unlike traditional weight-loss interventions that primarily focus on appetite suppression or caloric restriction, GDNF directly enhances the body's natural ability to burn fat and increase metabolic efficiency."
“This partnership is instrumental in our efforts to advance HT-KIT, a promising therapeutic aimed at targeting c-Kit in cancer treatments, We are committed to driving innovative solutions that can transform patient care."
Why Hoth Therapeutics (NASDAQ: HOTH) Stands Out
Hoth Therapeutics (NASDAQ: HOTH) is redefining early-stage pharmaceutical research by developing innovative therapies that address critical unmet medical needs. Unlike many biotech firms that focus solely on commercialization, Hoth specializes in identifying, advancing, and accelerating promising drug candidates from pre-clinical research to clinical trials. By
working closely with leading scientists, clinicians, and key opinion leaders, the company ensures that its treatments are designed to make a real impact on patient outcomes.
At the core of Hoth’s innovation is a diversified pipeline spanning multiple therapeutic areas. The company is developing HT-001, a topical formulation
currently in Phase II trials, aimed at treating skin disorders caused by tyrosine kinase inhibitor therapy. Additionally, Hoth is advancing HT-KIT for mast-cell-derived cancers and anaphylaxis, HT-TBI for traumatic brain injury and ischemic stroke, and HT-ALZ as a potential treatment for Alzheimer’s disease. Its focus on respiratory and inflammatory conditions includes HT-004 for asthma and allergies, HT-003 for acne, psoriasis, and inflammatory bowel diseases, and HT-005 for lupus
treatment.
Beyond individual drug candidates, Hoth is pioneering the BioLexa Platform, a proprietary drug compound designed to revolutionize dermatology. This patented technology, currently in clinical trials for eczema, takes a proactive approach to treating skin conditions by targeting their underlying causes rather than just managing symptoms. Such innovations set Hoth apart in the biotech space, demonstrating its commitment to pushing the boundaries of treatment possibilities.
What truly
differentiates Hoth Therapeutics is its strategic collaborations with some of the world’s top research institutions. The company has secured licensing agreements with George Washington University, Virginia Commonwealth University, North Carolina State University, and the University of Cincinnati, among others. These partnerships allow Hoth to integrate cutting-edge discoveries into its pipeline, accelerating the development of groundbreaking therapies. A notable research collaboration with Weill
Cornell Medicine further underscores its commitment to scientific advancement and medical innovation.
Under the leadership of CEO Robb Knie, Hoth operates with agility and
efficiency, focusing on innovation while maintaining a patient-first philosophy. Unlike larger biotech firms burdened by bureaucracy, Hoth’s streamlined approach enables rapid decision-making and resource optimization, ensuring that its treatments move swiftly from development to clinical application. The company’s philosophy, Innovating for Everyone, reflects its mission to improve the quality of life for all patients, regardless of their medical condition.
With a strong pipeline, groundbreaking research partnerships, and a
mission-driven approach to patient care, Hoth Therapeutics is at the forefront of medical innovation. As the company continues to advance its clinical programs and expand its impact, it is poised to reshape the future of treatment options across multiple disease areas, making a lasting difference in the lives of patients worldwide.
The Future of Innovative Therapies:
Advancing Treatments for Alzheimer’s, Cancer, Stroke, and More
The pharmaceutical industry has long been challenged by complex diseases such as Alzheimer’s, cancer, traumatic brain injury (TBI), stroke, and inflammatory conditions. While significant strides have been made in understanding their underlying mechanisms, effective and accessible treatments remain elusive for millions worldwide. However,
recent advancements in biotechnology and targeted therapeutics are reshaping the landscape, bringing renewed hope to patients and healthcare providers alike.
A History of Persistent Challenges
For decades, conditions like Alzheimer’s disease have remained at the forefront of
neurodegenerative research. Since its discovery by Dr. Alois Alzheimer in 1906, the disease has been linked to amyloid-beta plaques and tau tangles, yet treatments addressing these pathological markers have seen limited success. Similarly, cancer therapies have evolved from traditional chemotherapy to more sophisticated approaches like immunotherapy, yet many forms of cancer still lack highly effective treatment options. Stroke and TBI, often resulting in long-term neurological deficits, also
present significant hurdles due to the complexity of brain repair mechanisms.
A Rapidly Growing Industry
The global market for neurological and oncological treatments is expanding rapidly. The Alzheimer's therapeutics market, for instance, is projected to grow from $4.82 billion in 2023 to approximately $8.18 billion by 2032, reflecting a compound annual growth rate (CAGR) of 8.7%.
Similarly, the oncology drugs market is anticipated to increase from $220.80 billion in 2024 to $518.25 billion by 2032, with a CAGR of 11.3%.
This growth is driven by advancements in targeted therapies and immunotherapies, offering more precise and effective treatment options. The increasing prevalence of neurological conditions and cancer underscores the urgent need for innovative therapies to improve
patient outcomes.
Hoth Therapeutics Pioneering the Next Wave of Treatments
Hoth Therapeutics (NASDAQ: HOTH) is at the forefront of this evolution, developing groundbreaking therapies across multiple disease areas. The company’s pipeline includes:
HT-ALZ: A promising Alzheimer’s disease treatment designed to reduce amyloid-beta levels, with preclinical studies demonstrating cognitive improvements in animal models. (Source)
HT-TBI: A novel therapy aimed at treating secondary brain injuries caused by stroke and traumatic brain injury, developed for use in
both healthcare and emergency settings. (Source)
HT-KIT: A cutting-edge treatment targeting mast-cell-derived cancers, with preclinical research paving the way for future clinical trials. (Source)
Hoth Therapeutics (NASDAQ: HOTH) - Key Metrics
Hoth Therapeutics (NASDAQ: HOTH) has a market cap or net worth of $14.068 million as of March 13, 2025. Its market cap has increased by a staggering 46.32% in one year.
Important Dates The next estimated earnings date is Thursday, March 27, 2025, after market close.
Analysts Ratings
Hoth Therapeutics (NASDAQ: HOTH) has garnered strong support from analysts, with
a 12-month average price target of $4.75, representing a potential upside of 339.81% from the current price of $1.08. Analysts have given HOTH a "Strong Buy" rating, signaling confidence in the stock's growth potential.
Latest Analyst Forecasts: Jason Kolbert (D. Boral Capital) – Maintains Strong Buy rating, Price Target: $5 (+362.96%) [March 10, 2025]
Jason Kolbert (D. Boral Capital) – Maintains Strong Buy rating, Price Target: $5 (+362.96%) [March 6, 2025]
Jason Kolbert (D. Boral Capital) – Maintains Strong Buy rating, Price Target: $5 (+362.96%) [March 4, 2025]
Jason Kolbert (D. Boral Capital) – Maintains Strong Buy rating, Price Target: $5 (+362.96%) [Feb 11, 2025]
With multiple analysts maintaining bullish ratings, Hoth Therapeutics is positioned as a promising investment opportunity in the biotech sector.
Why Now is the Time to Consider Hoth Therapeutics (NASDAQ: HOTH)
Hoth Therapeutics (NASDAQ: HOTH) is shaping up to be a high-potential biotech opportunity, with strong
analyst backing and a pipeline of groundbreaking treatments targeting cancer, Alzheimer’s, inflammatory bowel disease, atopic dermatitis, and more.
Technically, HOTH is trading at $1.08, with a 12-month analyst target of $4.75, signaling a potential 339% upside. With a Strong Buy rating from multiple analysts and price targets
reaching $7.00, bullish momentum is building. Our own outlook envisions a 100% surge in sight, driven by growing investor interest and breakthrough advancements in drug development.
Beyond the charts, Hoth’s patient-focused approach and strategic collaborations position it as a key player in early-stage biotech innovation. By
advancing promising therapies from research to clinical trials, the company is paving the way for next-generation treatments that could reshape the industry.
With institutional interest rising and Hoth targeting multi-billion-dollar healthcare markets, this stock offers an opportunity for both immediate momentum and long-term
growth.
Don’t overlook Hoth Therapeutics (NASDAQ: HOTH)—a major breakout could be on the horizon.
As always, we encourage you to conduct your own research and consider how Hoth Therapeutics (NASDAQ:
HOTH) fits into your broader investment strategy.
This newsletter is a Paid Advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by DEXWireNews LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to DEXWireNews LLC.
You are reading this
newsletter because you have subscribed via our opt-In signup form on our website. If you have been subscribed by accident, then you may unsubscribe by clicking the link below.
By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or
licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research
and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our
website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be
based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here: We do NOT own shares of any of the companies mentioned herewithin, nor intend to buy any in the future.
You should read and review, if and to the extent available, any information concerning an advertised company available at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at http://www.sec.gov and the Financial Industry Regulatory Authority (the "FINRA") at http://www.FINRA.org. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud
at https://www.sec.gov/reportspubs/investor-publications/investorpubscyberfraudhtm.html, as well as related information published on how to invest carefully. You are responsible for verifying all claims and conducting your own
due diligence. You agree and acknowledge that any hyperlinks to the website of (1) an advertised company, (2) the party issuing or preparing the information for the advertised company, or (3) other information contained in our disseminated emails is provided only for your reference and convenience. We are not responsible for the accuracy or reliability of these external sites, nor are we responsible for the content, advertising, opinions, products or other materials on external sites or
information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated email or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on us, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink. You also acknowledge that we are not an investment advisory
service, a broker-dealer or an investment adviser. You acknowledge that you will consult with your own advisers regarding any decisions as to any advertised company.
Our business model is to receive financial compensation to promote public companies. We have been compensated fifteen thousand dollars electronically via bank wire by
One Eyed Jack Enterprises LLC for an advertising / marketing campaign for Hoth Therapeutics (NASDAQ: HOTH) beginning on 3/13/2025 on 3/18/2025. DEXWireNews may receive additional campaigns in the future by One Eyed Jack Enterprises LLC to distribute media for Hoth Therapeutics (NASDAQ: HOTH).
Any compensation is a major conflict of
interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our
database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements,
which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is
not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, we often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before
publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without
notice.
Will everyone receive the Information at the same time? No. The Information may be sent to potential investors at different times that
are minutes, hours, days or even weeks apart.
How is a potential investor impacted if they receive the Information later than other investors? If the trading volume and price of a Profile Issuer’s securities increases after the Information is provided to an earlier group of investors, then subsequent investors will pay inflated prices for any securities of the Profiled Issuers that they purchase. This will likely result in the Profiled Issuers having trading losses.
